Wang, Cheng-YouCheng-YouWangHsia, Jiun-YiJiun-YiHsiaLi, Che-HsingChe-HsingLiCHAO-CHI HOChao, Wan-RuWan-RuChaoWu, Ming-FangMing-FangWu2021-11-022021-11-022021-05-2115257304https://scholars.lib.ntu.edu.tw/handle/123456789/586058• The incidence of non–small cell lung cancer with primary BRAF fusions is rare, and no therapeutics are approved to treat these gene alterations. • Herein, we report the first case with advanced lung adenocarcinoma harboring a novel de novo LIMD1-BRAF fusion that benefited from the mitogen-activated protein kinase kinase inhibitor trametinib. • This patient achieved partial response and had progression-free survival of more than 7 months. This observation supports the single use of the mitogen-activated protein kinase kinase inhibitor trametinib on BRAF fusions.enBRAF fusion; MAPK pathway; lung adenocarcinoma; precision medicine; trametinib[SDGs]SDG3case report10.1016/j.cllc.2021.05.003341487672-s2.0-85109111648https://scholars.lib.ntu.edu.tw/handle/123456789/571106